BACKGROUND: Adiposity is associated with cystatin C. Cystatin C-based glomerular filtration rate (GFR) equations may result in overestimation of chronic kidney disease (CKD) prevalence at greater body mass index (BMI) levels. STUDY DESIGN: Cross-sectional. SETTING & PARTICIPANTS: 6,709 US adult Third National Health and Nutrition Examination Survey participants. FACTOR: BMI. OUTCOME: Absolute percentage of difference in prevalence of stage 3 or 4 CKD between creatinine- and cystatin C-based estimating equations by level of BMI. MEASUREMENTS: Normal weight, overweight, and obesity were defined as BMI of 18.5 to less than 25.0, 25 to less than 30.0, and 30 kg/m(2) or greater, respectively. Stage 3 or 4 CKD (estimated glomerular filtration rate [eGFR], 15 to 59 mL/min/1.73 m(2)) was defined using the 4-variable creatinine-based Modification of Diet in Renal Disease Study equation (eGFR(MDRD)); cystatin C level, age, sex, and race equation (eGFR(CysC,age,sex,race)); cystatin C-only equation (eGFR(CysC)); cystatin C level of 1.12 mg/L or greater (increased cystatin C); and an equation incorporating serum creatinine level, cystatin C level, age, sex, and race (eGFR(Cr,CysC,age,sex,race)). RESULTS: Differences in stage 3 or 4 CKD prevalence estimates between eGFR(CysC,age,sex,race), eGFR(CysC), and increased cystatin C, separately, and eGFR(MDRD) were greater at higher BMI levels. Specifically, compared with estimates derived using eGFR(MDRD) for normal-weight, overweight, and obese participants, estimated prevalences of stage 3 or 4 CKD were 2.1%, 3.0%, and 6.5% greater when estimated by using eGFR(CysC,age,sex,race) (P trend = 0.005); 0.1%, 0.6%, and 2.2% greater for eGFR(CysC) (P trend = 0.03); 2.9%, 5.2%, and 9.5% greater for increased cystatin C (P trend < 0.001); and -0.1%, -0.4%, and 0.0% greater for eGFR(Cr,CysC,age,sex,race), respectively (P trend = 0.7). LIMITATIONS: No gold-standard measure of GFR was available. CONCLUSIONS: BMI may influence the estimated prevalence of stage 3 or 4 CKD when cystatin C-based equations are used.
BACKGROUND: Adiposity is associated with cystatin C. Cystatin C-based glomerular filtration rate (GFR) equations may result in overestimation of chronic kidney disease (CKD) prevalence at greater body mass index (BMI) levels. STUDY DESIGN: Cross-sectional. SETTING & PARTICIPANTS: 6,709 US adult Third National Health and Nutrition Examination Survey participants. FACTOR: BMI. OUTCOME: Absolute percentage of difference in prevalence of stage 3 or 4 CKD between creatinine- and cystatin C-based estimating equations by level of BMI. MEASUREMENTS: Normal weight, overweight, and obesity were defined as BMI of 18.5 to less than 25.0, 25 to less than 30.0, and 30 kg/m(2) or greater, respectively. Stage 3 or 4 CKD (estimated glomerular filtration rate [eGFR], 15 to 59 mL/min/1.73 m(2)) was defined using the 4-variable creatinine-based Modification of Diet in Renal Disease Study equation (eGFR(MDRD)); cystatin C level, age, sex, and race equation (eGFR(CysC,age,sex,race)); cystatin C-only equation (eGFR(CysC)); cystatin C level of 1.12 mg/L or greater (increased cystatin C); and an equation incorporating serum creatinine level, cystatin C level, age, sex, and race (eGFR(Cr,CysC,age,sex,race)). RESULTS: Differences in stage 3 or 4 CKD prevalence estimates between eGFR(CysC,age,sex,race), eGFR(CysC), and increased cystatin C, separately, and eGFR(MDRD) were greater at higher BMI levels. Specifically, compared with estimates derived using eGFR(MDRD) for normal-weight, overweight, and obeseparticipants, estimated prevalences of stage 3 or 4 CKD were 2.1%, 3.0%, and 6.5% greater when estimated by using eGFR(CysC,age,sex,race) (P trend = 0.005); 0.1%, 0.6%, and 2.2% greater for eGFR(CysC) (P trend = 0.03); 2.9%, 5.2%, and 9.5% greater for increased cystatin C (P trend < 0.001); and -0.1%, -0.4%, and 0.0% greater for eGFR(Cr,CysC,age,sex,race), respectively (P trend = 0.7). LIMITATIONS: No gold-standard measure of GFR was available. CONCLUSIONS: BMI may influence the estimated prevalence of stage 3 or 4 CKD when cystatin C-based equations are used.
Authors: Irina Kratchmarova; Dario E Kalume; Blagoy Blagoev; Philipp E Scherer; Alexandre V Podtelejnikov; Henrik Molina; Perry E Bickel; Jens S Andersen; Minerva M Fernandez; Jacob Bunkenborg; Peter Roepstorff; Karsten Kristiansen; Harvey F Lodish; Matthias Mann; Akhilesh Pandey Journal: Mol Cell Proteomics Date: 2002-03 Impact factor: 5.911
Authors: Josef Coresh; Brad C Astor; Geraldine McQuillan; John Kusek; Tom Greene; Frederick Van Lente; Andrew S Levey Journal: Am J Kidney Dis Date: 2002-05 Impact factor: 8.860
Authors: Eric L Knight; Jacobien C Verhave; Donna Spiegelman; Hans L Hillege; Dick de Zeeuw; Gary C Curhan; Paul E de Jong Journal: Kidney Int Date: 2004-04 Impact factor: 10.612
Authors: Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan Journal: Ann Intern Med Date: 2003-07-15 Impact factor: 25.391
Authors: Meredith C Foster; Shih-Jen Hwang; Stacy A Porter; Joseph M Massaro; Udo Hoffmann; Caroline S Fox Journal: Hypertension Date: 2011-09-19 Impact factor: 10.190
Authors: Li Fan; Lesley A Inker; Jerome Rossert; Marc Froissart; Peter Rossing; Michael Mauer; Andrew S Levey Journal: Nephrol Dial Transplant Date: 2014-01-20 Impact factor: 5.992
Authors: Aaron R Folsom; Pamela L Lutsey; Brad C Astor; Keattiyoat Wattanakit; Susan R Heckbert; Mary Cushman Journal: Nephrol Dial Transplant Date: 2010-03-29 Impact factor: 5.992
Authors: Jeannette M Beasley; Aaron K Aragaki; Andrea Z LaCroix; Marian L Neuhouser; Lesley F Tinker; Jane A Cauley; Kristine E Ensrud; Rebecca D Jackson; Ross L Prentice Journal: J Nutr Date: 2011-06-08 Impact factor: 4.798
Authors: Morgan E Grams; Stephen P Juraschek; Elizabeth Selvin; Meredith C Foster; Lesley A Inker; John H Eckfeldt; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2013-04-22 Impact factor: 8.860
Authors: Angelos A Evangelopoulos; Natalia G Vallianou; Vassiliki P Bountziouka; Amalia N Giotopoulou; Maria S Bonou; John Barbetseas; Peter C Avgerinos; Demosthenes B Panagiotakos Journal: Cardiol Res Pract Date: 2010-10-14 Impact factor: 1.866